Xeris Biopharma Holdings, Inc. XERS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $12.01M+127% | $554K+101% | -$15.64M+75.2% | -$32M+46.3% | -$45.08M+30.0% | ||
| $1.34M+9.8% | $1.31M+7.0% | $1.29M+2.5% | $1.26M-6.3% | $1.22M-16.1% | ||
| $22.06M+15.9% | $22.37M+21.8% | $20.69M+18.0% | $19.81M+49.8% | $19.04M+59.7% | ||
| $3.36M+2.7% | $3.31M+10.4% | $3.27M+21.0% | $3.27M+30.7% | $3.27M+42.1% | ||
| —— | —— | —— | —— | —— | ||
| $14.82M+47.2% | $19.29M+120% | $18.41M+161% | $15.38M+88.6% | $10.07M-24.4% | ||
| $119K— | -$69K— | -$3.57M— | —— | —— | ||
| —— | —— | —— | —— | -$3.81M— | ||
| -$2.05M-298% | $3.99M+472% | -$1.72M-140% | -$1.54M-141% | -$515K-112% | ||
| —— | $0-100% | $20.75K-85.4% | $41.5K-79.4% | $62.25K-76.1% | ||
| —— | —— | $3.66M— | —— | —— | ||
| $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | ||
| $582K+17.3% | $537K-3.2% | $495K-23.6% | $461K-42.2% | $496K-45.0% | ||
| -$1.66M— | -$1.58M— | —— | —— | —— | ||
| $48.53M+269% | $28.63M+173% | $8.58M— | -$18.15M— | -$28.68M— | ||
| -$1.01M— | -$696K— | $9.65M— | —— | —— | ||
| $7.56M— | $11.58M— | $10.54M— | —— | —— | ||
| $19.9M+140% | $10.88M+191% | $9.5M+163% | $9.11M+153% | $8.3M+132% | ||
| —— | —— | —— | —— | -$2.08M— | ||
| $53.21M+1,323% | $39.32M+866% | $32.26M— | $1.58M— | -$4.35M— | ||
| $32.47M+27.6% | $27.12M+0.6% | $26.19M-1.3% | $31.72M+52.5% | $25.45M+31.4% | ||
| $3.36M+2.7% | $3.31M+10.4% | $3.27M+21.0% | $3.27M+30.7% | $3.27M+42.1% | ||
| $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | $10.84M0.0% | ||
| —— | —— | —— | —— | $4.29M+22.8% | ||
| —— | —— | $25.93M+2,605% | $11.24M+80.1% | $5.16M-9.2% | ||
| -$1.66M— | -$1.58M— | —— | —— | —— | ||
| —— | —— | $3.66M— | —— | —— | ||
| $582K+17.3% | $537K-3.2% | $495K-23.6% | $461K-42.2% | $496K-45.0% | ||
| -$1.01M-40.6% | -$696K+19.8% | -$583K+25.3% | -$599K+42.3% | -$717K+67.2% | ||
| -$1.66M— | -$1.58M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $15.15M— | $3.19M— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Xeris Biopharma Holdings, Inc. generate?
- Xeris Biopharma Holdings, Inc. (XERS) generated $48.5M in operating cash flow over the trailing twelve months.
- Where does Xeris Biopharma Holdings, Inc.'s cash flow data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
